---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-023293"
form_type: "8-K"
ticker: "BLGO"
cik: "0000880242"
company_name: "BIOLARGO, INC."
filed_at: "2025-07-23T23:59:59+00:00"
generated_at: "2026-05-18T03:57:26.539118+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioLargo mid-year update: Clyra distribution deals, Cellinity MOUs, PFAS project; Pooph sales drag

## Summary
- Clyra Medical secured distribution agreements covering 6,100 hospitals, 6,300 ASCs, 2,200 wound care clinics; raised $3.3M in new capital.
- Cellinity battery signed four MOUs with JV partners; each factory >$100M build, $500M annual revenue capacity; targets enterprise value >$2B.
- First paid PFAS treatment project in New Jersey underway; AEC removes PFAS below 4 ppt; CEO named to U.S. Dept of Commerce ETTAC.
- ONM (Pooph) sales decline led to increased AR, lower cash, downward stock pressure; payback arrangement and new Pooph ads launched.
- BLEST engineering revenues grew 152% YoY in Q1 2025; potential multimillion-dollar projects in pipeline.

## SEC filing metadata
- accession: 0001437749-25-023293
- form_type: 8-K
- ticker: BLGO
- cik: 0000880242
- company_name: BIOLARGO, INC.
- filed_at: 2025-07-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/880242/000143774925023293/0001437749-25-023293-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/880242/000143774925023293/blgo20250723_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-023293
- JSON: https://secwatch.observer/filing/0001437749-25-023293.json
- Plain text: https://secwatch.observer/filing/0001437749-25-023293.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.